Kiniksa Pharmaceuticals officer sells 194k in stock

KNSA Stock  USD 21.51  0.53  2.53%   
About 58% of all Kiniksa Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Kiniksa Pharmaceuticals suggests that some traders are interested. The current market sentiment, together with Kiniksa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Kiniksa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
  
Kiniksa Pharmaceuticals officer sells 194k in stock

Read at investing.com
Investing News at Macroaxis
  

Kiniksa Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Kiniksa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Kiniksa Pharmaceuticals Fundamental Analysis

We analyze Kiniksa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiniksa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiniksa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Asset

Total Asset Comparative Analysis

Kiniksa Pharmaceuticals is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Kiniksa Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kiniksa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Kiniksa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiniksa Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Kiniksa Pharmaceuticals Related Equities

CHRSCoherus BioSciences   12.58   
0%
100.0%
KRONKronos Bio   8.51   
0%
67.0%
LRMRLarimar Therapeutics   7.31   
0%
58.0%
GPCRStructure Therapeutics   6.75   
0%
53.0%
PHATPhathom Pharmaceuticals   5.88   
0%
46.0%
LYRALyra Therapeutics   5.00   
0%
39.0%
CGEMCullinan Oncology   4.98   
0%
39.0%
GOSSGossamer Bio   4.17   
0%
33.0%
BOLTBolt Biotherapeutics   3.57   
0%
28.0%
NVCTNuvectis Pharma   2.31   
0%
18.0%
DAWNDay One   2.15   
0%
17.0%
SPROSpero Therapeutics   0.86   
0%
6.0%
NUVLNuvalent   0.62   
0%
4.0%
REPLReplimune   0.23   
0%
1.0%
KURAKura Oncology   0.37   
2.0%
0%
COGTCogent Biosciences   1.11   
8.0%
0%
ACLXArcellx   2.16   
17.0%
0%
VTYXVentyx Biosciences   3.46   
27.0%
0%

Complementary Tools for Kiniksa Stock analysis

When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules